WaveMan
WaveMan · Company
CYDY · Cytodyn Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CYDY CytoDyn (CYDY) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001175680
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
1
13F, latest reported quarter

CytoDyn insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for CytoDyn Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
1 fund bought in last quarter
the lowest in Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.5% of the float short (float per yahoo 2026-10-27) · 15.2 days to cover · settled 2026-10-15
below 62% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CYDY

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-12.9%12M
-24%+0%+24%+48%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CYDY: institutional holders (13F)

13F holdings, latest reported quarter
DIVERSIFIED TRUST CO
45,790 sh
$10.9K
Williams Jones Wealth Management, LLC.
45,001 sh
$10.7K
Next Capital Management LLC
25,000 sh
$6.0K
HORIZON FINANCIAL SERVICES, LLC
18,200 sh
$4.3K
CAZ INVESTMENTS LP
12,000 sh
$2.9K

Congress trades in CYDY

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CYDY planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
18 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
10
Phase 2
1 active
2
Not applicable
0 active
5
Multi-phase
0 active
What changed recently
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Pr
2026-10-27 · Available → Temporarily Not Available
,
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 1 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CYDY financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$266.0K
four quarters, 2021-06-01 to 2022-05-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$22.6M
operating cash flow minus capex, 2025-09-01 to 2026-08-31
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.63x
TTM operating cash flow over long-term debt only, 2026-08-31
Return on equity
n/a
average equity is zero or negative
Return on assets
-351.0%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$339.4M
market value at close 2026-10-27 on 2026-09-30 shares, plus long-term debt only, 2026-08-31, minus cash 2026-08-31
FCF yield
-7.1%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-052025-052024-052023-05
Revenuen/an/an/a$0
Operating income-$38.6M$9.7M-$18.1M-$40.6M
Net income-$42.7M$3.7M-$49.8M-$79.8M
EPS (diluted)-0.030.00-0.05-0.10
Operating cash flow-$17.3M-$8.8M-$11.0M-$25.1M
Cash$11.9M$11.9M$3.1M$2.5M
Long-term debt$38.3M$45.4M$45.0M$45.7M
SEC XBRL, fiscal years, as known on 2026-10-28

CYDY Stock Sonar score 4/7 axes

Find similar shapesCompare

CYDY ranks highest on risk and compliance (77th percentile) and financial health (58th), and lowest on institutional and government (1st), among Pharma & Biotech peers.

Financial health
58
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.63x · 58 pct, sector of 371
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
0
Inputs
  • Funds adding, latest quarter1 · 0 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
77
Inputs
  • Short interest, % of float+2.5% · 69 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+4.7% · 84 pct, sector of 511
3 not measured: Profitability, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; pre-tax loss, no effective tax rate to apply
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies